Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.
- DOI
- 10.1016/j.esmoop.2025.106056
- Published
- 2026 Feb
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2025.106056,
title = {Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.},
author = {Liu X and Ou K and Ma X and Yang W and Cao B and Lu J and Zhang L and Gao L and Wang Q and Zhang W and Jiang Z and Zhou A and Zhang H and Yang L},
year = {2026},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2025.106056},
url = {https://doi.org/10.1016/j.esmoop.2025.106056}
}RIS
TY - JOUR TI - Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study. AU - Liu X AU - Ou K AU - Ma X AU - Yang W AU - Cao B AU - Lu J AU - Zhang L AU - Gao L AU - Wang Q AU - Zhang W AU - Jiang Z AU - Zhou A AU - Zhang H AU - Yang L PY - 2026 JO - ESMO open DO - 10.1016/j.esmoop.2025.106056 UR - https://doi.org/10.1016/j.esmoop.2025.106056 ER -
APA
X, L., K, O., X, M., W, Y., B, C., J, L., L, Z., L, G., Q, W., W, Z., Z, J., A, Z., H, Z., & L, Y. (2026). Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.. ESMO open. https://doi.org/10.1016/j.esmoop.2025.106056
Source records
- pubmed · retrieved 2026-09-27T16:07:01.737Z